Drug intelligence / Profile preview

HRS9950

Development stage: Phase 2
Lead developer: Hengrui Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

HRS9950 is an investigational small molecule drug developed as an oral agonist of Toll-like receptor 8 (TLR8). Its primary mechanism of action is to activate TLR8, which plays a role in modulating the innate immune response. The drug is being developed by Jiangsu Hengrui Medicine for the treatment of chronic hepatitis B, with clinical trials conducted in China. As of early 2025, it has reached Phase 2 clinical development for this indication and has not been approved in any country. There are no known brand names or additional indications reported at this time[1][3].

Targets

TLR8 (Toll-like receptor 8)

Beyond the preview

Go deeper on HRS9950.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HRS9950.

Explore the full profile